比马酰胺 | 155205-89-3

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 比马酰胺
• 中文别名: (5Z)-7-{(1R,2R,3R,5S)-3,5-二羟基-2-[(3S)-3-羟基-5-苯基-1-戊烯-1-基]环戊基}-5-庚烯酰胺
• 英文名称: 17-phenyl-trinor-PGF2alpha amide
• 英文别名: (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]hept-5-enamide
• CAS: 155205-89-3
• 化学式: C₂₃H₃₃NO₄
• 分子量: 387.5
• InChiKey: RAGQWYIPCPFTJC-KDACTHKWSA-N

物化性质

• 沸点：
  618.3±55.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：30mg/mL； DMSO：20mg/mL；乙醇：20mg/mL； PBS（pH 7.2）：2 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  104
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Ripple Therapeutics Corporation

  公开号：US20210347809A1

  公开（公告）日：2021-11-11

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本文描述了可加工的组合物，其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法，包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力（IOP）和/或其他理想活性的类固醇和前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
• COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH
  申请人：Allergan, Inc.

  公开号：EP3421030A1

  公开（公告）日：2019-01-02

  The invention provides a composition suitable for topical application, the composition comprising bimatoprost and one or more penetration enhancers selected from fatty acids, benzyl alcohol, fatty alcohols, straight chain C4-C20 saturated monocarboxylic and dicarboxylic acids, methyl laurate, ethyl oleate, polyethylene glycol monolaurate, propylene glycol monolaurate, propylene glycol dilaurate, glycerol monolaurate, glycerol monooleate, isopropyl n-decanoate, octyldodecyl myristate, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, and compounds wherein a C2-C4 alkane diol or triol is substituted with one or two fatty ether substituents. The composition is useful for the therapeutic and non-therapeutic stimulation of hair growth.

  丙二醇单月桂酸酯、丙二醇二月桂酸酯、甘油单月桂酸酯、甘油单油酸酯、正癸酸异丙酯、肉豆蔻酸辛基十二酯、二乙二醇单甲醚、二乙二醇单乙醚，以及 C2-C4 烷二醇或三醇被一个或两个脂肪醚取代基取代的化合物。该组合物可用于治疗性和非治疗性刺激毛发生长。
• Heterodimer compositions and methods for the treatment of ocular disorders
  申请人：Ripple Therapeutics Corporation

  公开号：US11279729B2

  公开（公告）日：2022-03-22

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本描述涉及一种可处理组合物，所述组合物包含至少一个以自由形式可处理的单元。此外，本描述还涉及用于治疗眼科疾病或紊乱（包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（例如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞）的组合物和方法。所述组合物和方法包含具有抗炎活性、降低眼内压以及/或其它有益活性的类固醇和前列腺素。将所述组合物注射入眼中，为患有眼科疾病患者带来治疗益处。
• [EN] HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS<br/>[FR] COMPOSITIONS HÉTÉRODIMÈRES ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：RIPPLE THERAPEUTICS CORP

  公开号：WO2021220061A2

  公开（公告）日：2021-11-04

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.